Brief: Ipsen: Impact Of Iqirvo On Fatigue
07/05/2025 07:04
May 7 (Reuters) - Ipsen SA IPN.PA: LATE-BREAKING EXPLORATORY DATA HIGHLIGHTS THE IMPACT OF IQIRVO® (ELAFIBRANOR) ON FATIGUE AND PROVIDES MECHANISTIC INSIGHTS INTO ANTI-INFLAMMATORY AND SYMPTOM-RELATED EFFECTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IQIRVO DUAL PPARΑ/Δ ACTIVATION IMPACTS INFLAMMATION AND FIBROSIS PPARΑ ACTIVATION LINKED TO FATIGUE IMPROVEMENT IN PRIMARY BILIARY CHOLANGITIS Source text: ID:nGNX5jtmST Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients